| A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) (NCT05218902) | Bristol-Myers Squibb | 2022-02-25 |
| A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT) (NCT04264806) | Janssen Research & Development, LLC | 2021-05-06 |
| Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (NCT04266301) | Novartis Pharmaceuticals | 2020-06-08 |
| A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems (NCT03814005) | Takeda | 2019-07-10 |
| IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome (NCT03175978) | IGF Oncology, LLC | 2018-02-21 |
| Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) (NCT03268954) | Takeda | 2017-11-28 |
| A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML) (NCT03040401) | Vastra Gotaland Region | 2017-02-15 |
| Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs (NCT02907359) | Astex Pharmaceuticals, Inc. | 2017-01-13 |
| Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia (NCT02807272) | Kura Oncology, Inc. | 2017-01-10 |
| A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes (NCT02841540) | Hemavant Sciences GmbH | 2016-10-06 |
| An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) (NCT02610777) | Millennium Pharmaceuticals, Inc. | 2016-04-14 |
| Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT (NCT02472691) | Heinrich-Heine University, Duesseldorf | 2015-05-01 |
| Myeloproliferative Neoplasms (MPNs) Patient Registry (NCT02760238) | University Health Network, Toronto | 2015-04-01 |
| Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (NCT02201329) | Boehringer Ingelheim | 2014-08-01 |
| Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML (NCT01957644) | Boehringer Ingelheim | 2013-11-06 |
| Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment) (NCT02085798) | Celgene | 2012-12-17 |
| An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands (NCT02891551) | Celgene | 2012-05-01 |
| Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine (NCT01519011) | Celgene | 2012-02-07 |
| Korean Post-marketing Surveillance for Sprycel® (NCT01464047) | Bristol-Myers Squibb | 2011-10-01 |
| Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma (NCT00761722) | Celgene | 2008-08-12 |
| Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS (NCT00744536) | Sunnybrook Health Sciences Centre | 2008-01-01 |
| Sorafenib in Myelodysplastic Syndrome (NCT00510289) | Duke University | 2006-07-01 |
| Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) (NCT00255346) | M.D. Anderson Cancer Center | 2005-11-15 |
| Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) (NCT00109538) | Merck Sharp & Dohme LLC | 2005-05-01 |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS (NCT00025662) | National Heart, Lung, and Blood Institute (NHLBI) | 2001-05-01 |